Age-related brain expression and regulation of the chemokine CCL4/MIP-1β in APP/PS1 double-transgenic mice

Journal of Neuropathology and Experimental Neurology

Volumn 73, Issue 4, 2014, Pages 362-374

  Zhu, Min ^a   Allard, Joanne S ^c   Zhang, Yongqing ^b   Perez, Evelyn ^a   Spangler, Edward L ^a   Becker, Kevin G ^b   Rapp, Peter R ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Alzheimer disease; ATF3; CCL4 MIP 1A; Epigenetics; Neuroinflammation

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 3; AMYLOID BETA PROTEIN; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MESSENGER RNA;

ALZHEIMER DISEASE; ANIMAL TISSUE; ARTICLE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DISEASE COURSE; DNA METHYLATION; FEMALE; GENETIC TRANSCRIPTION; INFLAMMATION; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; VASCULAR AMYLOIDOSIS;

ACTIVATING TRANSCRIPTION FACTOR 3; AGING; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; CHEMOKINE CCL4; CHROMATIN IMMUNOPRECIPITATION; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; GLIAL FIBRILLARY ACIDIC PROTEIN; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUTATION; PRESENILIN-1;

EID: 84897402181     PISSN: 00223069     EISSN: 15546578     Source Type: Journal    
DOI: 10.1097/NEN.0000000000000060     Document Type: Article

References (55)

1. Gorelick PB. Role of inflammation in cognitive impairment: Results of observational epidemiological studies and clinical trials. Ann N Y Acad Sci 2010;1207:155-62
2. Perry VH, Cunningham C, Holmes C. Systemic infections and inflammation affect chronic neurodegeneration. Nat Rev Immunol 2007;7:161-67
3. Minagar A, Shapshak P, Fujimura R, et al. The role of macrophage/microglia and astrocytes in the pathogenesis of three neurologic disorders: HIVassociated dementia, Alzheimer disease, and multiple sclerosis. J Neurol Sci 2002;202:13-23
4. Schmidtmayerova H, Nottet HS, Nuovo G, et al. Human immunodeficiency virus type 1 infection alters chemokine beta peptide expression in human monocytes: Implications for recruitment of leukocytes into brain and lymph nodes. Proc Natl Acad Sci U S A 1996;93:700-4
5. Kelder W, McArthur JC, Nance-Sproson T, et al. Beta-chemokines MCP-1 and RANTES are selectively increased in cerebrospinal fluid of patients with human immunodeficiency virus-Associated dementia. Ann Neurol 1998;44:831-35
6. Glass JD, Fedor H, Wesselingh SL, et al. Immunocytochemical quantitation of human immunodeficiency virus in the brain: Correlations with dementia. Ann Neurol 1995;38:755-62
7. Pulliam L. HIV regulation of amyloid beta production. J Neuroimmune Pharmacol 2009;4:213-17
8. Xia MQ, Qin SX, Wu LJ, et al. Immunohistochemical study of the beta-chemokine receptors CCR3 and CCR5 and their ligands in normal and Alzheimer's disease brains. Am J Pathol 1998;153:31-37
9. Patel NS, Paris D, Mathura V, et al. Inflammatory cytokine levels correlate with amyloid load in transgenic mouse models of Alzheimer's disease. J Neuroinflammation 2005;2:9
10. Ito S, Sawada M, Haneda M, et al. Amyloid-beta peptides induce several chemokine mRNA expressions in the primary microglia and Ra2 cell line via the PI3K/Akt and/or ERK pathway. Neurosci Res 2006;56:294-99
11. Smits HA, Rijsmus A, van Loon JH, et al. Amyloid-betaYinduced chemokine production in primary human macrophages and astrocytes. J Neuroimmunol 2002;127:160-68
12. Proffitt J, Crabtree G, Grove M, et al. An ATF/CREB-binding site is essential for cell-specific and inducible transcription of the murine MIP-1 beta cytokine gene. Gene 1995;152:173-79
13. Widmer U, Manogue KR, Cerami A, et al. Genomic cloning and promoter analysis of macrophage inflammatory protein (MIP)-2, MIP-1 alpha, and MIP-1 beta, members of the chemokine superfamily of proinflammatory cytokines. J Immunol 1993;150:4996-5012
14. Liang G, Wolfgang CD, Chen BP, et al. ATF3 gene. Genomic organization, promoter, and regulation. J Biol Chem 1996;271:1695-701
15. Hai TW, Liu F, Coukos WJ, et al. Transcription factor ATF cDNA clones: An extensive family of leucine zipper proteins able to selectively form DNA-binding heterodimers. Genes Dev 1989;3:2083-90
16. Khuu CH, Barrozo RM, Hai T, et al. Activating transcription factor 3 (ATF3) represses the expression of CCL4 in murine macrophages. Mol Immunol 2007;44:1598-605
17. Hunt D, Hossain-Ibrahim K, Mason MRJ, et al. ATF3 upregulation in glia during Wallerian degeneration: Differential expression in peripheral nerves and CNS white matter. BMC Neurosci 2004;5:12
18. Yin X, Dewille JW, Hai T. A potential dichotomous role of ATF3, an adaptive-response gene, in cancer development. Oncogene 2008;27:2118-27
19. HartmanMG, Lu D, Kim ML, et al. Role for activating transcription factor 3 in stress-induced beta-cell apoptosis. Mol Cell Biol 2004;24:5721-32
20. An J, Tsunekawa K, Feng GG, et al. Roles of naofen, a novel WD-repeat-2 protein, in the CCl4-Treated liversYa possible relationship to cell proliferation. Eur J Pharmacol 2008;587:285-90
21. Borchelt DR, Ratovitski T, van Lare J, et al. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 1997;19:939-45
22. Sabbagh JJ, Kinney JW, Cummings JL. Animal systems in the development of treatments for Alzheimer's disease: Challenges, methods, and implications. Neurobiol Aging 2013;34:169-83
23. Maia LF, Kaeser SA, Reichwald J, et al. Changes in amyloid-beta and Tau in the cerebrospinal fluid of transgenic mice overexpressing amyloid precursor protein. Sci Transl Med 2013;5:194re2
24. Guzik-Kornacka A, Sliwa A, Plucinska G, et al. Status epilepticus evokes prolonged increase in the expression of CCL3 and CCL4 mRNA and protein in the rat brain. Acta Neurobiol Exp (Wars) 2011;71:193-207
25. Johnson-Wood K, Lee M, Motter R, et al. Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease. Proc Natl Acad Sci U S A 1997;94:1550-55
26. Wirths O, Multhaup G, Czech C, et al. Intraneuronal APP/A beta trafficking and plaque formation in beta-Amyloid precursor protein and presenilin-1 transgenic mice. Brain Pathol 2002;12:275-86
27. Duffy AM, Holscher C. The incretin analogue D-Ala2 GIP reduces plaque load, astrogliosis and oxidative stress in an APP/PS1 mouse model of Alzheimer's disease. Neuroscience 2013;228:294-300
28. Kamphuis W, Mamber C, Moeton M, et al. GFAP isoforms in adult mouse brain with a focus on neurogenic astrocytes and reactive astrogliosis in mouse models of Alzheimer disease. PLoS One 2012;7:e42823
29. Minkeviciene R, Ihalainen J, Malm T, et al. Age-related decrease in stimulated glutamate release and vesicular glutamate transporters in APP/PS1 transgenic and wild-Type mice. J Neurochem 2008;105:584-94
30. Yan P, Bero AW, Cirrito JR, et al. Characterizing the appearance and growth of amyloid plaques in APP/PS1 mice. J Neurosci 2009;29:10706-14
31. Hanifi-Moghaddam P, Kappler S, Seissler J, et al. Altered chemokine levels in individuals at risk of Type 1 diabetes mellitus. Diabet Med 2006; 23:156-63
32. Koch AE, Kunkel SL, Shah MR, et al. Macrophage inflammatory protein-1 beta: A C-C chemokine in osteoarthritis. Clin Immunol Immunopathol 1995;77:307-14
33. Capelli A, Di Stefano A, Gnemmi I, et al. Increased MCP-1 and MIP-1beta in bronchoalveolar lavage fluid of chronic bronchitics. Eur Respir J 1999;14:160-65
34. Bless NM, Huber-Lang M, Guo RF, et al. Role of CC chemokines (macrophage inflammatory protein-1 beta, monocyte chemoattractant protein-1, RANTES) in acute lung injury in rats. J Immunol 2000;164:2650-59
35. Manczak M, Jiang S, Orzechowska B, et al. Crucial role of CCL3/ MIP-1alpha in the recurrence of autoimmune anterior uveitis induced with myelin basic protein in Lewis rats. J Autoimmun 2002;18:259-70
36. Akiyama H, Barger S, Barnum S, et al. Inflammation and Alzheimer's disease. Neurobiol Aging 2000;21:383-421
37. Shukaliak JA, Dorovini-Zis K. Expression of the beta-chemokines RANTES and MIP-1 beta by human brain microvessel endothelial cells in primary culture. J Neuropathol Exp Neurol 2000;59:339-52
38. Wyss-Coray T, Loike JD, Brionne TC, et al. Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. Nat Med 2003;9:453-57
39. Apelt J, Ach K, Schliebs R. Aging-related down-regulation of neprilysin, a putative beta-Amyloid-degrading enzyme, in transgenic Tg2576 Alzheimer-like mouse brain is accompanied by an astroglial upregulation in the vicinity of beta-Amyloid plaques. Neurosci Lett 2003;339:183-86
40. Hai T, Wolfgang CD, Marsee DK, et al. ATF3 and stress responses. Gene Expr 1999;7:321-35
41. Chen BP, Liang G, Whelan J, et al. ATF3 and ATF3 delta Zip. Transcriptional repression versus activation by alternatively spliced isoforms. J Biol Chem 1994;269:15819-26
42. Hsu JC, Bravo R, Taub R. Interactions among LRF-1, JunB, c-Jun, and c-Fos define a regulatory program in the G1 phase of liver regeneration. Mol Cell Biol 1992;12:4654-65
43. Ameri K, Hammond EM, Culmsee C, et al. Induction of activating transcription factor 3 by anoxia is independent of p53 and the hypoxic HIF signalling pathway. Oncogene 2007;26:284-89
44. Chen BP,Wolfgang CD, Hai TW. Analysis of ATF3, a transcription factor induced by physiological stresses and modulated by gadd153/Chop10. Mol Cell Biol 1996;16:1157-68
45. Allen-Jennings AE, Hartman MG, Kociba GJ, et al. The roles of ATF3 in glucose homeostasis. A transgenic mouse model with liver dysfunction and defects in endocrine pancreas. J Biol Chem 2001;276:29507-14
46. Okamoto Y, Chaves A, Chen J, et al. Transgenic mice with cardiac-specific expression of activating transcription factor 3, a stress-inducible gene, have conduction abnormalities and contractile dysfunction. Am J Pathol 2001; 159:639-50
47. Marianayagam NJ, Sunde M, Matthews JM. The power of two: Protein dimerization in biology. Trends Biochem Sci 2004;29:618-25
48. Nilsson M, Ford J, Bohm S, et al. Characterization of a nuclear factor that binds juxtaposed with ATF3/Jun on a composite response element specifically mediating induced transcription in response to an epidermal growth factor/Ras/Raf signaling pathway. Cell Growth Differ 1997; 8:913-20
49. Yan C, Wang H, Boyd DD. ATF3 represses 72-kDa type IV collagenase (MMP-2) expression by antagonizing p53-dependent transactivation of the collagenase promoter. J Biol Chem 2002;277:10804-12
50. Yan C, Lu D, Hai T, et al. Activating transcription factor 3, a stress sensor, activates p53 by blocking its ubiquitination. Embo J 2005;24: 2425-35
51. Kang Y, Chen CR, Massague J. A self-enabling TGFbeta response coupled to stress signaling: Smad engages stress response factor ATF3 for Id1 repression in epithelial cells. Mol Cell 2003;11:915-26
52. Anderson AJ, Cummings BJ, Cotman CW. Increased immunoreactivity for Jun-And Fos-related proteins in Alzheimer's disease: Association with pathology. Exp Neurol 1994;125:286-95
53. Zhang P, Hirsch EC, Damier P, et al. c-fos protein-like immunoreactivity: Distribution in the human brain and overexpression in the hippocampus of patients with Alzheimer's disease. Neuroscience 1992;46:9-21
54. Anderson AJ, Su JH, Cotman CW. DNA damage and apoptosis in Alzheimer's disease: Colocalization with c-Jun immunoreactivity, relationship to brain area, and effect of postmortem delay. J Neurosci 1996;16:1710-19
55. Iguchi-Ariga SM, Schaffner W. CpG methylation of the cAMP-responsive enhancer/promoter sequence TGACGTCA abolishes specific factor binding as well as transcriptional activation. Genes Dev 1989;3:612-19